INTELLIA THERAPEUTICS, INC. (NTLA) Revenue 2016–2025
INTELLIA THERAPEUTICS, INC. (NTLA) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$67.7MFY2025 · since FY2016: $16.5M → $67.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $67.7M | +16.9% |
| FY2024 | $57.9M | +59.6% |
| FY2023 | $36.3M | -30.4% |
| FY2022 | $52.1M | +57.7% |
| FY2021 | $33.1M | -43.0% |
| FY2020 | $58.0M | +34.5% |
| FY2019 | $43.1M | +41.6% |
| FY2018 | $30.4M | +16.5% |
| FY2017 | $26.1M | +58.5% |
| FY2016 | $16.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NTLA financial trends
NTLA Net incomeNTLA Net marginNTLA Gross profitNTLA Gross marginNTLA Operating incomeNTLA Operating marginNTLA Operating cash flowNTLA Free cash flowNTLA Capital expendituresNTLA Return on equityNTLA Stock buybacksNTLA Dividends paidNTLA Total assetsNTLA Total liabilitiesNTLA Shareholders’ equityNTLA overview →